Esmond Tse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Esmond Tse has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alyona Ivanova
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada
1 shared publication - Kimia Ghannad-Zadeh
The Arthur and Sonia Labatt Brain Tumor Research Center, Hospital for Sick Children, Toronto, Canada
1 shared publication - Megan Wu
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada
1 shared publication - Robert Flick
University of Toronto
1 shared publication - Sunit Das
University of Toronto
1 shared publication - Taylor M. Wilson
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 22 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma
More than one third of patients with glioblastoma experience tumour progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier that to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumour recurrence in a mouse glioblastoma model, compared to treatment with TMZ alone. Our data identified lomitapide as a potential adjunct for treatment of temozolomide-resistant glioblastoma.
- 22 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Open AccessLomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma
More than one third of patients with glioblastoma experience tumour progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier that to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumour recurrence in a mouse glioblastoma model, compared to treatment with TMZ alone. Our data identified lomitapide as a potential adjunct for treatment of temozolomide-resistant glioblastoma.